Literature DB >> 11222340

Utility values associated with blindness in an adult population.

M M Brown1, G C Brown, S Sharma, J Kistler, H Brown.   

Abstract

AIM: To ascertain utility values associated with varying degrees of legal blindness.
METHODS: A cross sectional study on three group of patients. There were: (1) 15 patients with complete absence of vision (no light perception) in at least one eye who were asked to assume a scenario of no light perception in the second eye as well, (2) 17 patients with light perception to counting fingers in the better seeing eye, and (3) 33 patients with 20/200-20/400 vision in the better seeing eye. Utility values were measured using the time trade-off and standard gamble methods in each of the three groups.
RESULTS: The mean time trade-off utility value for the no light perception group with the theoretical scenario of bilateral absence of light perception was 0.26 (95% CI, 0.19-0.33). The mean utility value for the light perception to counting fingers group was 0.47 (95% CI, 0.33-0.61), and the mean utility value for the 20/200-20/400 group was 0.65 (95% CI, 0.58-0.72). Thus, patients with no light perception in one eye, who were presented with the same scenario in the second eye as well, were willing to trade almost 3 out of every 4 years of remaining life in return for perfect vision in each eye. Those with light perception to counting fingers would trade approximately 1 of 2 remaining years and those with 20/200-20/400 would trade approximately 1 of 3 remaining years.
CONCLUSIONS: There is a wide range of utility values associated with legal blindness. The utility value decreases dramatically with perceived total loss of vision (absence of light perception in each eye), compared with counting fingers to light perception vision, indicating that the preservation of even small amounts of vision in patients with legal blindness is critically important to their wellbeing and functioning in life.

Entities:  

Mesh:

Year:  2001        PMID: 11222340      PMCID: PMC1723892          DOI: 10.1136/bjo.85.3.327

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  Utilities and quality-adjusted life years.

Authors:  G W Torrance; D Feeny
Journal:  Int J Technol Assess Health Care       Date:  1989       Impact factor: 2.188

2.  Methodology for measuring health-state preferences--II: Scaling methods.

Authors:  D G Froberg; R L Kane
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

Review 3.  A clinician's guide to utility measurement.

Authors:  D A Redelmeier; A S Detsky
Journal:  Prim Care       Date:  1995-06       Impact factor: 2.907

4.  Explaining distortions in utility elicitation through the rank-dependent model for risky choices.

Authors:  P Wakker; A Stiggelbout
Journal:  Med Decis Making       Date:  1995 Apr-Jun       Impact factor: 2.583

5.  Markov models in medical decision making: a practical guide.

Authors:  F A Sonnenberg; J R Beck
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

6.  Patients' preferences in randomized clinical trials.

Authors:  M Angell
Journal:  N Engl J Med       Date:  1984-05-24       Impact factor: 91.245

Review 7.  Cost utility analysis: what should be measured?

Authors:  J Richardson
Journal:  Soc Sci Med       Date:  1994-07       Impact factor: 4.634

8.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

9.  Adding insult to injury. Usurping patients' prerogatives.

Authors:  J P Kassirer
Journal:  N Engl J Med       Date:  1983-04-14       Impact factor: 91.245

10.  Evidence-based medicine and cost-effectiveness.

Authors:  G C Brown; S Sharma; M M Brown; S Garrett
Journal:  J Health Care Finance       Date:  1999
View more
  52 in total

1.  The reproducibility of ophthalmic utility values.

Authors:  G C Brown; M M Brown; S Sharma; G Beauchamp; H Hollands
Journal:  Trans Am Ophthalmol Soc       Date:  2001

2.  Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension.

Authors:  Steven M Kymes; Michael R Plotzke; Michael A Kass; Michael V Boland; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2010-05

3.  A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes.

Authors:  M M Brown; G C Brown; S Sharma; A F Smith; J Landy
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

4.  Do routine eye exams improve vision?

Authors:  Gabriel Picone; Derek Brown; Frank Sloan; Paul Lee
Journal:  Int J Health Care Finance Econ       Date:  2004-03

5.  Cost-Utility Analysis of Glaucoma Medication Adherence.

Authors:  Paula Anne Newman-Casey; Mariam Salman; Paul P Lee; Justin D Gatwood
Journal:  Ophthalmology       Date:  2019-10-10       Impact factor: 12.079

6.  Utility analysis tells all.

Authors:  M Brown
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

Review 7.  The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Benjamin A Allaire; Michael S Song; Ronald Klein; Jinan B Saaddine
Journal:  Health Serv Res       Date:  2011-04-14       Impact factor: 3.402

8.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

9.  Preferences and Utilities for Health States after Treatment of Olfactory Groove Meningioma: Endoscopic versus Open.

Authors:  Christopher M Yao; Alyssa Kahane; Eric Monteiro; Fred Gentili; Gelareh Zadeh; John R de Almeida
Journal:  J Neurol Surg B Skull Base       Date:  2017-02-17

10.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.